glp 1 agonist osteoporosis GLP-1s and Bone Health: What the Evidence Says About Semaglutide, Bone Density, and Muscle Loss The Impact of GLP1 Agonists

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

Explore the transformative impact of GLP-1 medications on consumer behavior, food trends, and beyond

Supports gut lining integrity

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases